1,405 reports of this reaction
5.4% of all CANAKINUMAB reports
#1 most reported adverse reaction
PYREXIA is the #1 most commonly reported adverse reaction for CANAKINUMAB, manufactured by Novartis Pharmaceuticals Corporation. There are 1,405 FDA adverse event reports linking CANAKINUMAB to PYREXIA. This represents approximately 5.4% of all 25,877 adverse event reports for this drug.
Patients taking CANAKINUMAB who experience pyrexia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PYREXIA is moderately reported among CANAKINUMAB users, representing a notable but not dominant share of adverse events.
In addition to pyrexia, the following adverse reactions have been reported for CANAKINUMAB:
The following drugs have also been linked to pyrexia in FDA adverse event reports:
PYREXIA has been reported as an adverse event in 1,405 FDA reports for CANAKINUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
PYREXIA accounts for approximately 5.4% of all adverse event reports for CANAKINUMAB, making it one of the most commonly reported side effect.
If you experience pyrexia while taking CANAKINUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.